» Articles » PMID: 33183091

Time-course Analysis Reveals That Corticosteroids Resuscitate Diminished CD8+ T Cells in COVID-19: a Retrospective Cohort Study

Overview
Journal Ann Med
Publisher Informa Healthcare
Specialty General Medicine
Date 2020 Nov 13
PMID 33183091
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To illustrate the effect of corticosteroids and heparin, respectively, on coronavirus disease 2019 (COVID-19) patients' CD8+ T cells and D-dimer.

Methods: In this retrospective cohort study involving 866 participants diagnosed with COVID-19, patients were grouped by severity. Generalized additive models were established to explore the time-course association of representative parameters of coagulation, inflammation and immunity. Segmented regression was performed to examine the influence of corticosteroids and heparin upon CD8+ T cell and D-dimer, respectively.

Results: There were 541 moderate, 169 severe and 156 critically ill patients involved in the study. Synchronous changes of levels of NLR, D-dimer and CD8+ T cell in critically ill patients were observed. Administration of methylprednisolone before 14 DFS compared with those after 14 DFS ( = 0.154%, 95% CI=(0, 0.302), =.048) or a dose lower than 40 mg per day compared with those equals to 40 mg per day ( = 0.163%, 95% CI=(0.027, 0.295), =.020) significantly increased the rising rate of CD8+ T cell in 14-56 DFS.

Conclusions: The parameters of coagulation, inflammation and immunity were longitudinally correlated, and an early low-dose corticosteroid treatment accelerated the regaining of CD8+ T cell to help battle against SARS-Cov-2 in critical cases of COVID-19.

Citing Articles

Different treatment response to systemic corticosteroids according to white blood cell counts in severe COVID-19 patients.

Choi K, Kim D, Jin K, Lee H, Park T, Ryu B Ann Med. 2022; 54(1):2998-3006.

PMID: 36453635 PMC: 9721443. DOI: 10.1080/07853890.2022.2137736.


Mitochondrial Dysfunction Associates With Acute T Lymphocytopenia and Impaired Functionality in COVID-19 Patients.

Mo Y, To K, Zhou R, Liu L, Cao T, Huang H Front Immunol. 2022; 12:799896.

PMID: 35095881 PMC: 8795605. DOI: 10.3389/fimmu.2021.799896.


Prognostic value of lymphocyte count in severe COVID-19 patients with corticosteroid treatment.

Lu C, Chen B, Yang H, Hu H, Liu Y, Zhao Y Signal Transduct Target Ther. 2021; 6(1):106.

PMID: 33654057 PMC: 7921828. DOI: 10.1038/s41392-021-00517-3.


A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor.

Oz M, Lorke D, Kabbani N Pharmacol Ther. 2020; 221:107750.

PMID: 33275999 PMC: 7854082. DOI: 10.1016/j.pharmthera.2020.107750.

References
1.
Lin L, Lu L, Cao W, Li T . Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect. 2020; 9(1):727-732. PMC: 7170333. DOI: 10.1080/22221751.2020.1746199. View

2.
Shang L, Zhao J, Hu Y, Du R, Cao B . On the use of corticosteroids for 2019-nCoV pneumonia. Lancet. 2020; 395(10225):683-684. PMC: 7159292. DOI: 10.1016/S0140-6736(20)30361-5. View

3.
Tang N, Li D, Wang X, Sun Z . Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020; 18(4):844-847. PMC: 7166509. DOI: 10.1111/jth.14768. View

4.
Connors J, Levy J . COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020; 135(23):2033-2040. PMC: 7273827. DOI: 10.1182/blood.2020006000. View

5.
Scheinberg M, Blacklow N, Goldstein A, Parrino T, Rose F, Cathcart E . Influenza: response of T-cell lymphopenia to thymosin. N Engl J Med. 1976; 294(22):1208-11. DOI: 10.1056/NEJM197605272942204. View